ProSomnus® Announces Medicare Reimbursement for ProSomnus EVO® [PH] Sleep Apnea and Snoring Device
December 15, 2022 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision oral appliance therapy (OAT) for the treatment of Obstructive Sleep Apnea...
Study Published in "Military Medicine" Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy
December 08, 2022 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
Treatment with Precision Oral Appliance Therapy Demonstrated Significant Improvements in Apnea-Hypopnea Events, Respiratory Disturbances, Oxygen Saturation, REM Sleep, Sleep Efficiency and Sleepiness ...
ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices
December 06, 2022 17:55 ET
|
ProSomnus Sleep Technologies, Inc.
Completes business combination with Lakeshore Acquisition I Corp. ProSomnus common stock will trade on Nasdaq Capital Market under ticker symbol “OSA” SAN FRANCISCO, Dec. 06, 2022 (GLOBE NEWSWIRE)...
ProSomnus Reports Third Quarter Financial Results and Provides Corporate Update
November 29, 2022 08:30 ET
|
ProSomnus Sleep Technologies, Inc.
Generated record quarterly revenues, and expects merger with Lakeshore Acquisition I Corp. to close in the fourth quarter of 2022 Company Updates 2022 Revenue Guidance to range of $19.0 - $19.5...
ProSomnus® Announces FDA 510(k) Clearance for ProSomnus EVO™ [PH] Sleep and Snore Device
November 02, 2022 08:30 ET
|
ProSomnus Sleep Technologies, Inc.
Device expands ProSomnus’ suite of FDA-cleared Precision Oral Appliance Therapy Devices for treatment of Obstructive Sleep Apnea (OSA) Device is engineered to provide Medicare beneficiaries and...
ProSomnus® Sleep Technologies to Participate at the Oppenheimer Private Company Showcase
October 05, 2022 09:00 ET
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- ProSomnus Holdings Inc. (“ProSomnus”), the leader in patient preferred medical devices for the treatment of obstructive sleep apnea (OSA), today...
ProSomnus® Announces Availability of Insurance Reimbursement for Oral Appliance Therapy Devices in Germany
September 15, 2022 18:03 ET
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that the ProSomnus EVOTM Sleep...
ProSomnus Named to Inc. 5000 List of Fastest-Growing Companies for Fourth Consecutive Year
August 16, 2022 16:05 ET
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- ProSomnus (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that it has...
ProSomnus® to Host First Annual ProSleep Users Conference
July 29, 2022 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
SAN FRANCISCO, July 29, 2022 (GLOBE NEWSWIRE) -- ProSomnus, a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced it will host a first of its...
ProSomnus® to Open New Global Headquarters and Manufacturing Center of Excellence, Increasing Manufacturing Capacity and Efficiency
June 28, 2022 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
32,219-square-foot facility will quintuple growth and create local jobs All ProSomnus medical devices are made in Pleasanton, CA, USA SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- ProSomnus, a...